Argitalpenak (14) Ikertzaileren baten partaidetza izan duten argitalpenak

2013

  1. Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: Results from the ABEL study

    Thrombosis Research, Vol. 132, Núm. 6, pp. 666-670

  2. Basal/HER2 breast carcinomas Integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin)

    Cell Cycle, Vol. 12, Núm. 2, pp. 225-245

  3. Chemoradiation of rectal cancer

    Minerva Chirurgica, Vol. 68, Núm. 1, pp. 11-26

  4. Controversias actuales en angiogénesis y cáncer de pulmón: importancia de la histología para la optimización del tratamiento antiangiogénico en el cáncer de pulmón

    inScience Communications

  5. Dolor como factor predictor de depresión en el paciente oncológico: estudio de casos y controles. Estudio D-PRESS

    Revista de la Sociedad Espanola del Dolor, Vol. 20, Núm. 3, pp. 113-121

  6. Effects of Esomeprazole on the Pharmacokinetics of Lapatinib in Breast Cancer Patients

    Clinical Pharmacology in Drug Development, Vol. 2, Núm. 4, pp. 336-341

  7. Eribulin mesylate in breast cancer

    Women's Health, Vol. 9, Núm. 6, pp. 517-526

  8. Finding the right dose of fulvestrant in breast cancer

    Cancer Treatment Reviews, Vol. 39, Núm. 2, pp. 136-141

  9. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: Results from the GEICAM/2003-02 study

    Journal of Clinical Oncology

  10. Phase ii study of irinotecan in combination with capecitabine on a 3-weekly schedule as first-line chemotherapy for patients with metastatic or locally advanced colorectal cancer

    Journal of Analytical Oncology, Vol. 2, Núm. 3, pp. 151-159

  11. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): An open-label randomised study

    The Lancet Oncology, Vol. 14, Núm. 10, pp. 962-970

  12. Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. the large experience of the spanish national tumor registry (RGETNE)

    Neuroendocrinology, Vol. 98, Núm. 2, pp. 156-168

  13. SEOM clinical guidelines for the management of metastatic breast cancer 2013

    Clinical and Translational Oncology, Vol. 15, Núm. 12, pp. 1004-1010

  14. Thymidylate Synthase Expression Determines Pemetrexed Targets and Resistance Development in Tumour Cells

    PLoS ONE, Vol. 8, Núm. 5